Nomenclature	CCR1	CCR2	CCR3
HGNC, UniProt	CCR1, P32246	CCR2, P41597	CCR3, P51677
Endogenous agonists	CCL3 (CCL3, P10147) [342, 370, 783, 2228], CCL23 (CCL23, P55773) [342], CCL5 (CCL5, P13501) [370, 783], CCL7 (CCL7, P80098) [342, 703], CCL15 (CCL15, Q16663) [387], CCL14 (CCL14, Q16627) [342], CCL13 (CCL13, Q99616), CCL8 (CCL8, P80075)	CCL2 (CCL2, P13500) [387, 1224, 1347, 1533, 1996], CCL13 (CCL13, Q99616) [1224, 1996], CCL7 (CCL7, P80098) [387, 1224, 1996], CCL11 (CCL11, P51671) (Partial agonist) [1224, 1533], CCL16 (CCL16, O15467)	CCL13 (CCL13, Q99616) [1385, 1996], CCL24 (CCL24, O00175) [1385, 1533], CCL5 (CCL5, P13501) [409], CCL7 (CCL7, P80098) [409], CCL11 (CCL11, P51671) [480, 1009, 1385, 1700, 1996], CCL26 (CCL26, Q9Y258) [1009, 1385, 1533], CCL15 (CCL15, Q16663) [387], CCL28 (CCL28, Q9NRJ3), CCL8 (CCL8, P80075)
Agonists	–	–	CCL11 {Mouse} [409]
Endogenous antagonists	CCL4 (CCL4, P13236) (pK i 7.1–7.8) [342, 370]	CCL26 (CCL26, Q9Y258) (pIC50 8.5) [1533]	CXCL10 (CXCL10, P02778), CXCL11 (CXCL11, O14625), CXCL9 (CXCL9, Q07325)
Selective antagonists	BX 471 (pK i 8.2–9) [1164], compound 2b‐1 (pIC50 8.7) [1429], UCB35625 (pIC50 8) [1700], CP‐481,715 (pK d 8) [646]	GSK Compound 34 (pK i 7.6)	banyu (I) (Inverse agonist) (pK i 8.5) [2063], SB328437 (pK i 8.4), BMS compound 87b (pK i 8.1) [2048]
Labelled ligands	[125 I]CCL7 (human) (Agonist) [131], [125 I]CCL3 (human) (Agonist) [131, 656, 1719], [125 I]CCL5 (human) (Agonist) [1719]	[125 I]CCL2 (human) (Agonist), [125 I]CCL7 (human) (Agonist)	[125 I]CCL11 (human) (Antagonist) (pK d 8.3) [2063], [125 I]CCL5 (human) (Agonist), [125 I]CCL7 (human) (Agonist)